DiaCarta

DiaCarta is a commercial-stage diagnostics company with a focus on oncology and infectious diseases, utilizing its proprietary XNA and isobDNA™ technologies to enhance mutation detection sensitivity. Its product portfolio includes liquid biopsy tests for cancer therapy monitoring (RadTox™), colorectal cancer screening (ColoScape™), and bladder cancer detection (Oncuria®), alongside FDA-EUA infectious disease tests. The company has achieved significant commercial milestones, including Medicare coverage for RadTox™ and a statewide contract in Florida, supported by a CAP-accredited CLIA lab and global operations.

Proprietary XNA (Xenonucleic Acid) technology for high-sensitivity mutation enrichment in traditional sequencing/PCR platforms, and isobDNA™ (isothermal DNA) technology for signal amplification without nucleic acid extraction.

DiaCarta competes in the crowded precision oncology diagnostics market against major players like Guardant Health, Exact Sciences, and Natera, which have broader portfolios and greater sales reach. Its differentiation relies on its proprietary XNA and isobDNA™ technologies, which offer potential cost and sensitivity advantages in specific applications like therapy monitoring.